Overexpression of MiR-623 Suppresses Progression of Hepatocellular Carcinoma Via Regulating the PI3K/Akt Signaling Pathway by Targeting XRCC5
Overview
Cell Biology
Authors
Affiliations
It has been reported that miR-623 is deregulated in lung adenocarcinoma and inhibits tumor growth and invasion. However, it is unclear whether miR-623 has a role in the progression of hepatocellular carcinoma (HCC). Herein, we found that miR-623 was significantly downregulated in HCC, and that its expression was related to poor clinical outcomes of patients with HCC. Upregulation of miR-623 decreased cell proliferation, viability, migration, and invasion and further promoted apoptosis in 7721, Huh7, and Bel-7402 cells. Moreover, we also observed that miR-623 regulated the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), Wnt/β-catenin, and extracellular regulated protein kinases/c-Jun N-terminal kinase (ERK/JNK) signaling pathways as well as the expression level of related proteins. Further, X-ray repair cross complementing 5 (XRCC5) was a direct target for miR-623, and the suppression of PI3K/Akt, Wnt/β-catenin, and ERK/JNK signaling pathways and cell proliferation and invasion abilities caused by miR-623 in HCC cells was significantly reversed by the upregulation of XRCC5. Collectively, our data suggested that miR-623 suppressed the progression of HCC by regulating the PI3K/Akt, Wnt/β-catenin, and ERK/JNK pathways by targeting XRCC5 in HCC in vitro, indicating that miR-623 may be a target for the therapy of HCC.
Long Non-Coding RNAs H19 and HOTAIR Implicated in Intervertebral Disc Degeneration.
Wang Z, Zhang J, Zheng W, He Y Front Genet. 2022; 13:843599.
PMID: 35309146 PMC: 8927764. DOI: 10.3389/fgene.2022.843599.
Non-coding RNAs and glioblastoma: Insight into their roles in metastasis.
Mousavi S, Derakhshan M, Baharloii F, Dashti F, Mirazimi S, Mahjoubin-Tehran M Mol Ther Oncolytics. 2022; 24:262-287.
PMID: 35071748 PMC: 8762369. DOI: 10.1016/j.omto.2021.12.015.
Huang C, Yu W, Wang Q, Huang T, Ding Y J Hepatocell Carcinoma. 2021; 8:1339-1353.
PMID: 34786378 PMC: 8590609. DOI: 10.2147/JHC.S317256.
Wang F, Li X, Jia X, Geng L Cancer Manag Res. 2021; 13:1029-1039.
PMID: 33574702 PMC: 7871177. DOI: 10.2147/CMAR.S282162.
Cui D, Wang K, Liu Y, Gao J, Cui J Onco Targets Ther. 2020; 13:9291-9303.
PMID: 33061418 PMC: 7518774. DOI: 10.2147/OTT.S250497.